Dr Danny Wilson

Danny Wilson
Postdoctoral
School of Biological Sciences
Faculty of Sciences

Half of the world’s population is at risk of infection with mosquito-borne malaria parasites of the genus Plasmodium. These complex eukaryotic parasites that live inside human cells cause widespread sickness and death throughout tropical and sub-tropical regions of the world including countries neighbouring Australia. The majority of the >400,000 malaria related deaths that occur each year are caused by the parasite Plasmodium falciparum in children under 5 years in Africa, Asia and South America.
Unfortunately, resistance has developed to our most effective anti-malarial drugs, resulting in poorer treatment outcomes for clinical cases of this deadly parasite. There is an urgent need to identify novel drugs to partner with current first-line treatments to fill this looming treatment gap. In addition, development of an effective vaccine would reduce the burden of disease and greatly facilitate efforts to eradicate malaria. Unfortunately, a highly effective vaccine to protect against malaria has not been developed to date and efforts to identify the best vaccine targets are ongoing.
My laboratory seeks to identify and characterise novel parasite proteins for their suitability as both drug and vaccine targets. We focus on invasion of the human red blood cell by the small invasive merozoite stage of the parasite lifecycle as a therapeutic target. By developing therapeutics (drugs and vaccines) that inhibit merozoite invasion of the red blood cell we can instantly disrupt the lifecycle of the parasite in the stage that causes all the symptoms of the disease. We apply a breakthrough P. falciparum merozoite purification method (PNAS, 2010) that is superior to alternatives for studying malaria parasite invasion biology, opening up new opportunities to study this previously intractable lifecycle stage (Figure 1).

Antimalarials that inhibit invasion
By applying state of the art methods, we aim to develop invasion inhibitory antimalarials as viable drugs in a climate of increasing resistance to frontline treatments. Using a highly reproducible flow cytometry approach (Antimicrobial Agents & Chemotherapy, 2013; Figure 2 A & B), we have screened traditional antimalarial therapies, protease inhibitors, kinase inhibitors, a range of antibiotics and identified several compounds and there analogues that rapidly inhibit merozoite invasion (BMC Biology, 2015). To understand how drug-like compounds target the essential process of merozoite invasion, we apply mutation analysis of gene targets, phenotypic screens of related Apicomplexan parasites, modifications and screens of analogues, fluorescence microscopy localisation and proteomic identification of drug binding targets. Importantly, many of the invasion inhibitory compounds identified in our research also kill at other stages of the parasites complex lifecycle, increasing there utility as broad acting antimalarials. Development of these invasion inhibitory compounds and identification of the mechanisms by which they inhibit invasion is the subject of ongoing research in the laboratory.

Functional characterisation of poorly defined merozoite vaccine targets
The function of nearly 50% of the genes in P. falciparum parasites is poorly described or not known altogether. Malaria proteins involved in invasion are no exception with a large number of potential vaccine targets having no known function. We apply gene-editing techniques to examine the potential role of some of these proteins in invasion and parasite growth. Using fluorescence microscopy, flow cytometry, genetic manipulation and proteomic techniques, we are characterising the localisation, interactions and functions of merozoite antigens with no known function to test their suitability as therapeutic targets.

Connect With Me

Dr Danny Wilson

Half of the world’s population is at risk of infection with mosquito-borne malaria parasites of the genus Plasmodium. These complex eukaryotic parasites that live inside human cells cause widespread sickness and death throughout tropical and sub-tropical regions of the world including countries neighbouring Australia. The majority of the >400,000 malaria related deaths that occur each year are caused by the parasite Plasmodium falciparum in children under 5 years in Africa, Asia and South America.
Unfortunately, resistance has developed to our most effective anti-malarial drugs, resulting in poorer treatment outcomes for clinical cases of this deadly parasite. There is an urgent need to identify novel drugs to partner with current first-line treatments to fill this looming treatment gap. In addition, development of an effective vaccine would reduce the burden of disease and greatly facilitate efforts to eradicate malaria. Unfortunately, a highly effective vaccine to protect against malaria has not been developed to date and efforts to identify the best vaccine targets are ongoing.
My laboratory seeks to identify and characterise novel parasite proteins for their suitability as both drug and vaccine targets. We focus on invasion of the human red blood cell by the small invasive merozoite stage of the parasite lifecycle as a therapeutic target. By developing therapeutics (drugs and vaccines) that inhibit merozoite invasion of the red blood cell we can instantly disrupt the lifecycle of the parasite in the stage that causes all the symptoms of the disease. We apply a breakthrough P. falciparum merozoite purification method (PNAS, 2010) that is superior to alternatives for studying malaria parasite invasion biology, opening up new opportunities to study this previously intractable lifecycle stage (Figure 1).

Antimalarials that inhibit invasion
By applying state of the art methods, we aim to develop invasion inhibitory antimalarials as viable drugs in a climate of increasing resistance to frontline treatments. Using a highly reproducible flow cytometry approach (Antimicrobial Agents & Chemotherapy, 2013; Figure 2 A & B), we have screened traditional antimalarial therapies, protease inhibitors, kinase inhibitors, a range of antibiotics and identified several compounds and there analogues that rapidly inhibit merozoite invasion (BMC Biology, 2015). To understand how drug-like compounds target the essential process of merozoite invasion, we apply mutation analysis of gene targets, phenotypic screens of related Apicomplexan parasites, modifications and screens of analogues, fluorescence microscopy localisation and proteomic identification of drug binding targets. Importantly, many of the invasion inhibitory compounds identified in our research also kill at other stages of the parasites complex lifecycle, increasing there utility as broad acting antimalarials. Development of these invasion inhibitory compounds and identification of the mechanisms by which they inhibit invasion is the subject of ongoing research in the laboratory.

Functional characterisation of poorly defined merozoite vaccine targets
The function of nearly 50% of the genes in P. falciparum parasites is poorly described or not known altogether. Malaria proteins involved in invasion are no exception with a large number of potential vaccine targets having no known function. We apply gene-editing techniques to examine the potential role of some of these proteins in invasion and parasite growth. Using fluorescence microscopy, flow cytometry, genetic manipulation and proteomic techniques, we are characterising the localisation, interactions and functions of merozoite antigens with no known function to test their suitability as therapeutic targets.

Half of the world’s population is at risk of infection with mosquito-borne malaria parasites of the genus Plasmodium. These complex eukaryotic parasites that live inside human cells cause widespread sickness and death throughout tropical and sub-tropical regions of the world including countries neighbouring Australia. The majority of the >400,000 malaria related deaths that occur each year are caused by the parasite Plasmodium falciparum in children under 5 years in Africa, Asia and South America.

Unfortunately, resistance has developed to our most effective anti-malarial drugs, resulting in poorer treatment outcomes for clinical cases of this deadly parasite. There is an urgent need to identify novel drugs to partner with current first-line treatments to fill this looming treatment gap. In addition, development of an effective vaccine would reduce the burden of disease and greatly facilitate efforts to eradicate malaria. Unfortunately, a highly effective vaccine to protect against malaria has not been developed to date and efforts to identify the best vaccine targets are ongoing.

My laboratory seeks to identify and characterise novel parasite proteins for their suitability as both drug and vaccine targets. We focus on invasion of the human red blood cell by the small invasive merozoite stage of the parasite lifecycle as a therapeutic target. By developing therapeutics (drugs and vaccines) that inhibit merozoite invasion of the red blood cell we can instantly disrupt the lifecycle of the parasite in the stage that causes all the symptoms of the disease. We apply a breakthrough P. falciparum merozoite purification method (PNAS, 2010) that is superior to alternatives for studying malaria parasite invasion biology, opening up new opportunities to study this previously intractable lifecycle stage (Figure 1).

Antimalarials that inhibit invasion

By applying state of the art methods, we aim to develop invasion inhibitory antimalarials as viable drugs in a climate of increasing resistance to frontline treatments. Using a highly reproducible flow cytometry approach (Antimicrobial Agents & Chemotherapy, 2013; Figure 2 A & B), we have screened traditional antimalarial therapies, protease inhibitors, kinase inhibitors, a range of antibiotics and identified several compounds and there analogues that rapidly inhibit merozoite invasion (BMC Biology, 2015). To understand how drug-like compounds target the essential process of merozoite invasion, we apply mutation analysis of gene targets, phenotypic screens of related Apicomplexan parasites, modifications and screens of analogues, fluorescence microscopy localisation and proteomic identification of drug binding targets. Importantly, many of the invasion inhibitory compounds identified in our research also kill at other stages of the parasites complex lifecycle, increasing there utility as broad acting antimalarials. Development of these invasion inhibitory compounds and identification of the mechanisms by which they inhibit invasion is the subject of ongoing research in the laboratory.

Functional characterisation of poorly defined merozoite vaccine targets

The function of nearly 50% of the genes in P. falciparum parasites is poorly described or not known altogether. Malaria proteins involved in invasion are no exception with a large number of potential vaccine targets having no known function. We apply gene-editing techniques to examine the potential role of some of these proteins in invasion and parasite growth. Using fluorescence microscopy, flow cytometry, genetic manipulation and proteomic techniques, we are characterising the localisation, interactions and functions of merozoite antigens with no known function to test their suitability as therapeutic targets.

Postgraduate and undergraduate opportunities

Honours, summer-student, masters and PhD projects are available to explore the biology of the malaria parasite and to develop new therapies against this deadly infectious organism. We are a small, supportive, research team that is applying new technologies to discover new ways of ending the burden of malaria disease. If you would like to find out more about our current research opportunities and whether our research is right for you, please contact Dr. Danny Wilson (danny.wilson@adelaide.edu.au). 

Appointments

Date Position Institution name
2017 - 2019 DVCR 3 Year Mid-career Beacon Fellowship University of Adelaide, Adelaide
2015 Laboratory Head University of Adelaide
2014 - 2015 Senior Research Fellow (with Prof. James Paton) University of Adelaide
2014 Burnet Institute Research Fellow (Honorary) Burnet Institute, Melbourne
2012 - 2015 Peter Doherty, Early Career Fellowship National Health and Medical Research Council, Canberra
2011 - 2013 Senior Research Fellow (with Prof. Alan Cowman) Walter and Eliza Hall Institute of Medical Research, Melbourne
2009 - 2011 Research Officer (with Prof. James Beeson) Walter and Eliza Hall Institute of Medical Research, Melbourne

Awards and Achievements

Date Type Title Institution Name Amount
2017 - 2019 DVCR 3 Year Mid-career Beacon Fellowship University of Adelaide
2016 - 2016 DVCR Research Infrastructure Scheme (CIA)- Advanced Confocal Microscope ($342,000) University of Adelaide
2016 - 2016 DVCR Interdisciplinary Research Fund (CIA)- Imaris image analysis software ($48,211) University of Adelaide
2015 - 2015 DVCR Interdisciplinary Research Fund (CID)- Metalloproteomics HPLC ($28,000) University of Adelaide
2014 - 2016 NHMRC Project Grant (CIC)- ($607,484) Walter and Eliza Hall Institute
2012 - 2015 NHMRC Peter Doherty Early Career Fellowship National Health and Medical Research Institute
2004 - 2008 NHMRC Dora Lush PhD Scholarship National Health and Medical Research Centre

Education

Date Institution name Country Title
2004 - 2009 University of Melbourne, Melbourne Australia PhD

Keywords

Host-Parasite Interactions, Medical Parasitology, Tropical Medicine

Journals

Date Citation
2016 Hill,D, Wilson,D, Sampaio,N, Eriksson,E, Ryg-Cornejo,V, Abby Harrison,G, Uboldi,A, Robinson,L, Beeson,J, Siba,P et al, 2016, Merozoite antigens of plasmodium falciparum elicit strain-transcending opsonizing immunity, Infection and Immunity, 84, 8, 2175-2184 10.1128/IAI.00145-16
2016 Drew,D, Wilson,D, Elliott,S, Cross,N, Terheggen,U, Hodder,A, Siba,P, Chelimo,K, Dent,A, Kazura,J et al, 2016, A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens, BMC Medicine, 14, 1, 1-14 10.1186/s12916-016-0691-6
2016 Volz,J, Yap,A, Sisquella,X, Thompson,J, Lim,N, Whitehead,L, Chen,L, Lampe,M, Tham,W, Wilson,D et al, 2016, Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes, Cell Host and Microbe, 20, 1, 60-71 10.1016/j.chom.2016.06.004
2015 Josling,G, Petter,M, Oehring,S, Gupta,A, Dietz,O, Wilson,D, Schubert,T, Längst,G, Gilson,P, Crabb,B et al, 2015, A Plasmodium falciparum bromodomain protein regulates invasion gene expression, Cell Host and Microbe, 17, 6, 741-751 10.1016/j.chom.2015.05.009
2015 Wilson,D, Goodman,C, Sleebs,B, Weiss,G, de Jong,N, Angrisano,F, Langer,C, Baum,J, Crabb,B, Gilson,P et al, 2015, Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum, BMC Biology, 13, 1, 52-1-52-19 10.1186/s12915-015-0162-0
2014 Yap,A, Azevedo,MF, Gilson,PR, Weiss,GE, O'Neill,MT, Wilson,DW, Crabb,BS, Cowman,AF, 2014, Conditional expression of apical membrane antigen 1 in Plasmodium falciparum shows it is required for erythrocyte invasion by merozoites, Cellular Microbiology, 16, 5, 642-656 10.1111/cmi.12287
2013 Boyle,M, Wilson,D, Beeson,J, 2013, New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology, International Journal for Parasitology, 43, 1, 1-10 10.1016/j.ijpara.2012.11.002
2013 Wilson,D, Langer,C, Goodman,C, McFadden,G, Beeson,J, 2013, Defining the timing of action of antimalarial drugs against Plasmodium falciparum, Antimicrobial Agents and Chemotherapy, 57, 3, 1455-1467 10.1128/AAC.01881-12
2013 Regev-Rudzki,N, Wilson,D, Carvalho,T, Sisquella,X, Coleman,B, Rug,M, Bursac,D, Angrisano,F, Gee,M, Hill,A et al, 2013, Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles, Cell, 153, 5, 1120-1133 10.1016/j.cell.2013.04.029
2013 Healer,J, Thompson,J, Riglar,D, Wilson,D, Chiu,Y, Miura,K, Chen,L, Hodder,A, Long,C, Hansen,D et al, 2013, Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum, PLoS One, 8, 9, e72504-1-e72504-12 10.1371/journal.pone.0072504
2013 Persson,K, Fowkes,F, McCallum,F, Gicheru,N, Reiling,L, Richards,J, Wilson,D, Lopaticki,S, Cowman,A, Marsh,K et al, 2013, Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity, Journal of Immunology, 191, 2, 785-794 10.4049/jimmunol.1300444
2012 Reiling,L, Richards,J, Fowkes,F, Wilson,D, Chokejindachai,W, Barry,A, Tham,W, Stubbs,J, Langer,C, Donelson,J et al, 2012, The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria, PLoS One, 7, 9, e45253-1-e45253-12 10.1371/journal.pone.0045253
2012 Hill,D, Eriksson,E, Carmagnac,A, Wilson,D, Cowman,A, Hansen,D, Schofield,L, 2012, Efficient measurement of opsonising antibodies to plasmodium falciparum merozoites, PLoS One, 7, 12, e15692-1-e15692-10 10.1371/journal.pone.0051692
2012 Drew,D, Hodder,A, Wilson,D, Foley,M, Mueller,I, Siba,P, Dent,A, Cowman,A, Beeson,J, 2012, Defining the antigenic diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the requirements for a multi-allele vaccine against malaria, PLoS One, 7, 12, e51023-1-e51023-11 10.1371/journal.pone.0051023
2012 Marapana,D, Wilson,D, Zuccala,E, Dekiwadia,C, Beeson,J, Ralph,S, Baum,J, 2012, Malaria parasite signal peptide peptidase is an ER-resident protease required for growth but not for invasion, Traffic, 13, 11, 1457-1465 10.1111/j.1600-0854.2012.01402.x
2012 Taechalertpaisarn,T, Crosnier,C, Bartholdson,S, Hodder,A, Thompson,J, Bustamante,L, Wilson,D, Sanders,P, Wright,G, Rayner,J et al, 2012, Biochemical and functional analysis of two plasmodium falciparum blood-stage 6-cys proteins: P12 and P41, PLoS One, 7, 7, e41937-1-e41937-15 10.1371/journal.pone.0041937
2011 Riglar,D, Richard,D, Wilson,D, Boyle,M, Dekiwadia,C, Turnbull,L, Angrisano,F, Marapana,D, Rogers,K, Whitchurch,C et al, 2011, Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte, Cell Host & Microbe, 9, 1, 9-20 10.1016/j.chom.2010.12.003
2011 Arumugam,T, Takeo,S, Yamasaki,T, Thonkukiatkul,A, Miura,K, Otsuki,H, Zhou,H, Long,C, Sattabongkot,J, Thompson,J et al, 2011, Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen, Infection and Immunity, 79, 11, 4523-4532 10.1128/IAI.05412-11
2011 Lopaticki,S, Maier,A, Thompson,J, Wilson,D, Tham,W, Triglia,T, Gout,A, Speed,T, Beeson,J, Healer,J et al, 2011, Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites, Infection and Immunity, 79, 3, 1107-1117 10.1128/IAI.01021-10
2011 Wilson,D, Fowkes,F, Gilson,P, Elliott,S, Tavul,L, Michon,P, Dabod,E, Siba,P, Mueller,I, Crabb,B et al, 2011, Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans, PLoS One, 6, 11, e27705-1-e27705-14 10.1371/journal.pone.0027705
2011 Quelhas,D, Jimenez,A, Quinto,L, Serra-Casas,E, Mayor,A, Cistero,P, Puyol,L, Wilson,D, Richards,J, Nhampossa,T et al, 2011, IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine, Immunobiology, 216, 7, 793-802 10.1016/j.imbio.2010.12.010
2010 Tham,W, Wilson,D, Lopaticki,S, Schmidt,C, Tetteh-Quarcoo,P, Barlow,P, Richard,D, Corbin,J, Beeson,J, Cowman,A et al, 2010, Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand, Proceedings of the National Academy of Sciences of the United States of America, 107, 40, 17327-17332 10.1073/pnas.1008151107
2010 Boyle,M, Wilson,D, Richards,J, Riglar,D, Tetteh,K, Conway,D, Ralph,S, Baum,J, Beeson,J, 2010, Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development, Proceedings of the National Academy of Sciences of the United States of America, 107, 32, 14378-14383 10.1073/pnas.1009198107
2010 Ataide,R, Hasang,W, Wilson,D, Beeson,J, Mwapasa,V, Molyneux,M, Meshnick,S, Rogerson,S, 2010, Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria, PLoS One, 5, 5, e10807-1-e10807-10 10.1371/journal.pone.0010807
2010 Wilson,D, Crabb,B, Beeson,J, 2010, Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays, Malaria Journal, 9, 1, 1-12 10.1186/1475-2875-9-152
2009 Tham,W, Wilson,D, Reiling,L, Chen,L, Beeson,J, Cowman,A, 2009, Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium falciparum into human erythrocytes, Infection and Immunity, 77, 6, 2427-2435 10.1128/IAI.00048-09
2008 Dent,A, Bergmann-Leitner,E, Wilson,D, Tisch,D, Kimmel,R, Vulule,J, Sumba,P, Beeson,J, Angov,E, Moormann,A et al, 2008, Antibody-mediated growth inhibition of Plasmodium falciparum: Relationship to age and protection from parasitemia in Kenyan children and adults, PLoS One, 3, 10, e3557-1-e3557-10 10.1371/journal.pone.0003557
2006 AULIFF,A, WILSON,DW, RUSSELL,B, GAO,Q, CHEN,N, ANH,LN, MAGUIRE,J, BELL,D, O’NEIL,MT, CHENG,Q et al, 2006, AMINO ACID MUTATIONS IN PLASMODIUM VIVAX DHFR AND DHPS FROM SEVERAL GEOGRAPHICAL REGIONS AND SUSCEPTIBILITY TO ANTIFOLATE DRUGS, The American Journal of Tropical Medicine and Hygiene, 75, 4, 617-621
2005 BELL,DR, WILSON,DW, MARTIN,LB, 2005, FALSE-POSITIVE RESULTS OF A PLASMODIUM FALCIPARUM HISTIDINE-RICH PROTEIN 2–DETECTING MALARIA RAPID DIAGNOSTIC TEST DUE TO HIGH SENSITIVITY IN A COMMUNITY WITH FLUCTUATING LOW PARASITE DENSITY, The American Journal of Tropical Medicine and Hygiene, 73, 1, 199-203
2005 Duffy,MF, Byrne,TJ, Elliott,SR, Wilson,DW, Rogerson,SJ, Beeson,JG, Noviyanti,R, Brown,GV, 2005, Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype, Molecular Microbiology, 56, 3, 774-788 10.1111/j.1365-2958.2005.04577.x
2005 Chen,N, Wilson,DW, Pasay,C, Bell,D, Martin,LB, Kyle,D, Cheng,Q, 2005, Origin and Dissemination of Chloroquine-Resistant Plasmodium falciparum with Mutant pfcrt Alleles in the Philippines, Antimicrobial Agents and Chemotherapy, 49, 5, 2102-2105 10.1128/AAC.49.5.2102-2105.2005
2005 Elliott,SR, Duffy,MF, Byrne,TJ, Beeson,JG, Mann,EJ, Wilson,DW, Rogerson,SJ, Brown,GV, 2005, Cross-Reactive Surface Epitopes on Chondroitin Sulfate A-Adherent Plasmodium falciparum-Infected Erythrocytes Are Associated with Transcription of var2csa, Infection and Immunity, 73, 5, 2848-2856 10.1128/IAI.73.5.2848-2856.2005
2003 Wilson,P, Slade,R, Currie,BJ, Walton,SF, Holt,DC, Fischer,K, Allen,GE, Wilson,D, Kemp,DJ, 2003, Mechanisms for a Novel Immune Evasion Strategy in the Scabies Mite Sarcoptes Scabiei: A Multigene Family of Inactivated Serine Proteases, Journal of Investigative Dermatology, 121, 6, 1419-1424 10.1046/j.1523-1747.2003.12621.x
2003 Fischer,K, Chavchich,M, Huestis,R, Wilson,DW, Kemp,DJ, Saul,A, 2003, Ten families of variant genes encoded in subtelomeric regions of multiple chromosomes of Plasmodium chabaudi, a malaria species that undergoes antigenic variation in the laboratory mouse, Molecular Microbiology, 48, 5, 1209-1223 10.1046/j.1365-2958.2003.03491.x
2002 Pombo,DJ, Lawrence,G, Hirunpetcharat,C, Rzepczyk,C, Bryden,M, Cloonan,N, Anderson,K, Mahakunkijcharoen,Y, Martin,LB, Wilson,D et al, 2002, Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum, The Lancet, 360, 9333, 610-617 10.1016/S0140-6736(02)09784-2
2001 Wilson,D, Blanche,KR, Gibb,KS, 2001, Phytoplasmas and disease symptoms of crops and weeds in the semi-arid tropics of the Northern Territory, Australia, Australasian Plant Pathology, 30, 2, 159-163 10.1071/AP01015
2001 Holt,DC, Fischer,K, Tchavtchitch,M, Wilson,DW, Hauquitz,NE, Hawthorne,PL, Gardiner,DL, Trenholme,KR, Kemp,DJ, 2001, Clags in Plasmodium falciparum and other species of Plasmodium, Molecular and Biochemical Parasitology, 118, 2, 259-263 10.1016/S0166-6851(01)00378-4

2016 - University of Adelaide, DVCR, 3-Year Beacon Fellowship. CIA: Dr. Danny Wilson. ($340,000)

2016 - University of Adelaide, DVCR, Research Infrastructure Scheme. Advanced confocal microscope. CIA: Dr. Danny Wilson. ($342,000)

2016 - University of Adelaide, DVCR, Interdisciplinary Research Fund. Imaris microscopy analysis software. CIA: Dr. Danny Wilson($48,211)

2015 - University of Adelaide, DVCR, Interdisciplinary Research Fund. Metalloproteomics HPLC. CID: Dr. Danny Wilson. ($28,000)

2013 - NHMRC Project Grant: APP1057960. CIC Dr. Danny Wilson. ($607,484 3 years)

2011- NHMRC Peter Doherty Early Career Fellowship APP1035715. CIA Dr. Danny Wilson. ($290,032 4 years)

2004- NHMRC Dora Lush PhD Scholarship 2004-2008: APP305553. CIA: Dr. Danny Wilson. ($73,913)

  • 3rd Year: Infection and Immunity A, 2 lectures, Semester 1.
  • 2nd Year: Biomedical Science, 2 lectures, Semester 2.
  • 2nd Year: BSc Advance Mentor, Semester 1.
  • 1st Year: SGDE for human perspectives, Semester 2.

2017:   Principle supervisor, PhD candidate, School of Biological Sciences (2017 to present).

            Principle supervisor, BSc(Hons), School of Biological Sciences. 

2016:   Principle supervisor, PhD candidate, School of Biological Sciences (2016 to present).

            Principle supervisor, BSc(Hons), School of Biological Sciences. (1st Class, Dept. of Molecular and Cellular Biology).

2015:   Principle supervisor, BSc(Hons), School of Biological Sciences. (1st Class, Dept. of Molecular and Cellular Biology).

Memberships

Date Role Membership Country
2017 Member Light Microscopy Australia Australia
2014 Member Adelaide Protein Group Australia
2014 Member Australian Society for Biochemistry and Molecular Biology Australia
2013 Member Australian Society for Parasitology Australia

Committee Memberships

Date Role Committee Institution Country
2017 Secretary Molecular Life Sciences Microscopy Committee University of Adelaide Australia
2016 - 2018 Representative Australian Society for Parasitology, Education Committee Australian Society for Parasitology Australia
2013 - 2013 Treasurer Malaria in Melbourne Organising Committee Australia

Board Memberships

Date Role Board name Institution name Country
2016 - 2019 Representative Australian Society for Parasitology, SA Representative Australia
Position
Postdoctoral
Phone
83138259
Fax
8313 4362
Campus
North Terrace
Building
Molecular Life Sciences
Room Number
4 40
Org Unit
Molecular and Cellular Biology

top